Compare AMRC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | NTLA |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2010 | 2016 |
| Metric | AMRC | NTLA |
|---|---|---|
| Price | $26.37 | $13.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 20 |
| Target Price | ★ $37.88 | $20.45 |
| AVG Volume (30 Days) | 418.0K | ★ 3.6M |
| Earning Date | 03-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $1,769,928,000.00 | $67,671,000.00 |
| Revenue This Year | $10.66 | N/A |
| Revenue Next Year | $8.93 | $62.75 |
| P/E Ratio | $54.77 | ★ N/A |
| Revenue Growth | ★ 28.76 | 16.92 |
| 52 Week Low | $8.49 | $5.90 |
| 52 Week High | $44.93 | $28.24 |
| Indicator | AMRC | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 52.76 |
| Support Level | $26.29 | $12.55 |
| Resistance Level | $31.12 | $14.61 |
| Average True Range (ATR) | 1.60 | 0.72 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 30.56 | 41.52 |
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.